TITLE

PhRMA defends vulnerable Dems

AUTHOR(S)
Blake, Aaron; Wilson, Reid
PUB. DATE
June 2009
SOURCE
Hill;6/4/2009, Vol. 16 Issue 64, p11
SOURCE TYPE
Newspaper
DOC. TYPE
Article
ABSTRACT
The article reports that the Pharmaceutical Research and Manufacturers of America (PhRMA), who managing advertisement promotions for political parties in the U.S. will enjoy early congressional recess, thankful four Democratic freshmen for their early work in Congress.
ACCESSION #
42122327

 

Related Articles

  • PhRMA comes out on top in trade group rankings. Wilson, Megan R. // Hill;7/25/2013, Vol. 20 Issue 92, p12 

    The article reports on the results of a survey, conducted by APCO Worldwide, which found that Pharmaceutical Research & Manufacturers of America (PhRMA) might be the most effective lobby group in Washington.

  • PhRMA Worries About Defecit Reduction Efforts.  // Pharmaceutical Representative;Aug2011, Vol. 41 Issue 8, p8 

    The article reports on the opposition of the Pharmaceutical Research and Manufacturers of America (PhRMA) on a proposal to increase drug rebates in the U.S.

  • Pharma report shows strength of drug-development in Indiana.  // Indianapolis Business Journal;3/24/2014 Supplement, p13 

    The article discusses the report released by the Pharmaceutical Research and Manufacturers of America (PhRMA), a trade group representing the pharmaceutical research and biopharmaceutical companies in the U.S., on drug developments and clinical trials conducted in Indiana from 1999-2013.

  • PHRMA CELEBRATED. Arnold, Matthew // Medical Marketing & Media;May2010, Vol. 45 Issue 5, p10 

    The article mentions the fifth anniversary of the launch of Pharmaceutical Research and Manufacturers of America's (PhRMA's) Partnership for Prescription Assistance program.

  • Fight Forming on IP Protection.  // BioWorld Today;3/20/2013, Vol. 24 Issue 53, p3 

    The article reports that the Pharmaceutical Research and Manufacturers of America has called for prioritizing intellectual property protection, noting its importance to the development of innovative treatments.

  • 'PDUFA Spurs Innovation'.  // Chain Drug Review;2/27/2012, Vol. 34 Issue 4, p44 

    The article focuses on the role of Prescription Drug User Fee Act in biopharmaceutical innovation in the U.S. and also offers views of Pharmaceutical Research and Manufacturers of America's senior vice president for scientific and regulatory affairs David Wheadon on the same.

  • New Drug Development Requires Skill, Money, Persistence.  // Chain Drug Review;8/30/2010, Vol. 32 Issue 14, p106 

    The article reports on the claim of the Pharmaceutical Research and Manufacturers of America (PhRMA) that the approval process for new drugs is difficult in the U.S. and that new drug development needs skill, money, and persistence.

  • Head of AdvaMed Steps Down to Lead PhRMA.  // Medical Product Outsourcing;Oct2015, Vol. 13 Issue 8, p18 

    The article reports that Steve Ubl, president of Advanced Medical Technology Association, is resigning from his job to take over as president of Pharmaceutical Research and Manufacturers of America.

  • Pharmaceutical Lobby Reigns Supreme in Washington. Almashat, Sammy // Health Letter;Jun2014, p4 

    The article discusses the Pharmaceutical Research and Manufacturers of America (PhRMA) which is referred as pharmaceutical lobby which represent the drug industry depend on the two tried and true paths to the hearts of Washington's policy making elite money and connections.

  • PhRMA Supportive of Health Care Reform Effort.  // Chain Drug Review;1/18/2010, Vol. 32 Issue 2, p44 

    The article reports on the comprehensive health care reform supported by the Pharmaceutical Research and Manufacturers of America (PhRMA) in the U.S.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics